In our biweekly webinars, we have described the process of developing Prosetin—the first potential investigational drug to emerge from The Project ALS Therapeutics Core at
The Wasserman family has experienced first-hand the devastating effects of neurodegenerative diseases: Sandra Wasserman lost her beloved husband to Parkinson’s disease, and her son to
Last year, Project ALS launched The Project ALS Therapeutics Core at Columbia (THE CORE), a 3-year, $6.3M initiative toward the first meaningful therapies for ALS.
Project ALS is encouraged by the introduction of two bills that aim to provide people with ALS faster, more robust access to experimental therapies. These
Dear Friends, Project ALS is acutely aware of the unimaginable circumstances that Americans and people around the world are now facing. Our hearts, souls, and
Project ALS is excited to launch a new research partnership with the Medidata Institute targeting new, actionable insights into ALS disease progression and subtypes. Medidata
Project ALS is proud to once again be a bronze level charity sponsor for the 2020 TCS New York City Marathon. Thanks to the efforts
“Jaci is blazing a path that hopefully will not just cure her but set a course of treatment for countless others.” – Lori Hermstad, mother.
Give the gift of research this holiday season. Donate now.
What’s Prosetin? If you’ve been following Project ALS, you have probably heard us mention PHB, our working name for The Core’s first drug candidate-in-development. Now,
Since 2014, Project ALS has run an online campaign, the Don’t-Talk-a-Thon, during the month of May, in honor of ALS Awareness Month. For one day
Project ALS has partnered with Wine & Design, the awesome paint and sip franchise. During ALS Awareness month in May 2017 and 2018, Wine &
NEW MAILING ADDRESS
2585 Broadway, Suite 202
New York, NY 10025
Phone: (212) 420-7382
Email: [email protected]
Copyright Project ALS 2025 | Built with by Edward Kado
